Early genetic events in the development of high-grade serous ovarian cancer (HGSOC) may define the molecular basis of the profound structural and numerical instability of chromosomes in this disease. To discover candidate genetic changes we sequentially passaged cells from a karyotypically normal hTERT immortalised human ovarian surface epithelial line (IOSE25) resulting in the spontaneous formation of colonies in soft agar. Cell lines transformed ovarian surface epithelium 1 and 4 (TOSE 1 and 4) established from these colonies had an abnormal karyotype and altered morphology, but were not tumourigenic in immunodeficient mice. TOSE cells showed loss of heterozygosity (LOH) at TP53, increased nuclear p53 immunoreactivity and altered expression profile of p53 target genes. The parental IOSE25 cells contained a missense, heterozygous R175H mutation in TP53, whereas TOSE cells had LOH at the TP53 locus with a new R273H mutation at the previous wild-type TP53 allele. Cytogenetic and array CGH analysis of TOSE cells also revealed a focal genomic amplification of CXCR4, a chemokine receptor commonly expressed by HGSOC cells. TOSE cells had increased functional CXCR4 protein and its abrogation reduced epidermal growth factor receptor (EGFR) expression, as well as colony size and number. The CXCR4 ligand, CXCL12, was epigenetically silenced in TOSE cells and its forced expression increased TOSE colony size. TOSE cells had other cytogenetic changes typical of those seen in HGSOC ovarian cancer cell lines and biopsies. In addition, enrichment of CXCR4 pathway in expression profiles from HGSOC correlated with enrichment of a mutated TP53 gene expression signature and of EGFR pathway genes. Our data suggest that mutations in TP53 and amplification of the CXCR4 gene locus may be early events in the development of HGSOC, and associated with chromosomal instability.
INTRODUCTION
During the past 5 years there have been major advances in our understanding of the cellular and molecular biology of the human malignancies collectively referred to as ovarian cancer. Pathological and genomic findings indicate that some ovarian cancers are derived from non-ovarian tissues and that the different histotypes share few molecular similarities. 1 The major clinical feature that links 'ovarian' malignancies is frequent loco-regional dissemination to the ovary and related pelvic organs.
High-grade serous ovarian cancer (HGSOC) is the commonest and most lethal form, spreading throughout the peritoneum from its earliest stages. Although classically thought to arise from the ovarian surface epithelium or inclusion cysts 2 there is also a strong evidence that HGSOC may arise from the adjacent fallopian tube epithelium. 3 --5 Mutations in the tumour suppressor TP53, 6, 7 BRCA pathway disruption 8 and homologous recombination repair deficiency are the central genetic characteristics 1 and are associated with major structural and numerical chromosomal abnormalities. 7 Although mutation of TP53 is required for HGSOC, both clinical and in vitro studies suggest that it is not sufficient for transformation. 9, 10 Mouse models of HGSOC are complicated by significant differences in mouse anatomy and hormonal regulation. In order to accurately recapitulate this malignancy it is important that human cells are used. Karst et al. 10 established immortalised human fallopian tube secretory epithelial cells with hTERT and either SV40 large and small T antigens or sh-p53. Such cells could be fully transformed by oncogenic Ras or c-myc so that they formed peritoneal malignancies in immunosuppressed mice. Similar recent studies confirmed these observations with multiple molecular alterations of primary human fallopian tube cells leading to immortalisation, senescence or full transformation. 9 The finding of markers of genomic stress appears to be a unifying feature in these systems and also from studies of early invasions lesions in the fallopian tube. 1, 11 Several years ago we also used hTERT to immortalise ovarian surface epithelial cells (IOSE) obtained from surface brushing of the ovary during surgery for benign conditions. 12 More recently we monitored these IOSE cell lines for evidence of malignant transformation. Karyotypically normal immortalised cells from one of the donors spontaneously acquired the ability to grow in soft agar. These cells, that we have named transformed ovarian surface epithelium (TOSE), exhibited karyotypic abnormalities that are found in HGSOC tumours and cell lines, had altered p53 function through complex mutation events and amplification of the CXCR4 gene locus at chromosome 2q21.3. This gene amplification was reflected in de novo expression of CXCR4 mRNA and functional CXCR4 protein.
As loss of p53 function is a central characteristic of HGSOC, and CXCR4 is commonly found on HGSOC cells 13, 14 where it is an important component of an autocrine tumour-promoting network, 15 we suggest that TOSE cells may represent precursor cells of HGSOC and that CXCR4 expression may have a role in the earliest stages of this disease.
RESULTS

Spontaneous 'transformation' of ovarian surface epithelial cells
We previously established hTERT immortalised human ovarian surface epithelial cell lines, IOSE, from three individuals. All lines had a 46, XX karyotype with functional p53 and Rb pathways. 12 After repeated passage, one cell line, IOSE25, acquired the ability to form colonies in soft agar (Figure 1a ). Cell populations were isolated from these colonies and named TOSE. Microsatellite analysis confirmed that TOSE clones were derived from IOSE25 (Supplementary Table S1 ). Two clones, TOSE 1 and 4 were further characterised. The morphology of TOSE 1 and 4 cells was significantly altered, with an average circularity of 0.86±0.015 and 0.89±0.006, respectively, compared with 0.70±0.025 for IOSE25 (P ¼ 0.006 and 0.002). TOSE cells also showed increased nuclear staining for p53 (Figure 1b) and loss of heterozygosity (LOH) at the TP53 gene locus (Figure 1c ). p53 immunoreactivity generally correlates with increased p53 expression or altered stability, typically from missense mutations in the DNA-binding domain. 16 The transformed TOSE 1 cells had increased expression of p53 target genes as compared with IOSE25 with significant upregulation of 131 probes and downregulation in 93 probes (Figure 1d and Supplementary Table S2 ). Sanger sequencing of exons 2 --11 of TP53 showed that IOSE25 contained a heterozygous g.12512G4A mutation indicating a missense R175H amino-acid substitution. TOSE 1 and TOSE 4 had identical TP53 sequences with a g.13798G4A mutation (R273H amino-acid substitution) and g.12512G (wild-type codon 175). This is consistent with LOH at the TP53 locus with a new R273H mutation in the previously normal allele (Supplementary Table S3 ). These data suggested that several populations of cells might have been originally present within the cultures and that selection for the R273H mutation occurred during enrichment of the transformed phenotype. To accurately quantitate the proportion of different TP53 alleles during transformation we used digital PCR to determine the relative percentage of each mutated allele across a range of passages of IOSE25 cells and the donor normal NOSE25 cells from which the hTERT immortalised IOSE25 cells were derived (Figure 1e) . None of the NOSE25 cells had the R273H mutation of TP53, but a very small population of cells exhibited a R175H mutation. Between passages 14 --18 the IOSE25 cells still exhibited the R175H mutated allele but by passage 21 the TOSE cells displayed 100% prevalence of the R273H mutation.
As missense mutations in TP53 may represent an early driver in HGSOC, we speculated that TOSE cells might reflect precursors of HGSOC cells.
TP53 mutation is infrequent in other types of 'ovarian' cancer. 
Cytogenetic changes in TOSE cells and ovarian cancer samples We next compared cytogenetic abnormalities in TOSE cells with published data for ovarian cancer cell lines and biopsies. Gains in 3q, 12p, 20q and losses in 8p and 17p are common to TOSE cells and HGSOCs 17 --21 (Supplementary Tables S4 and S5 ).
TOSE cells have a functional amplification of CXCR4 As copy number alterations have been shown to be drivers of HGSOC we carried out detailed copy number analysis using Affymetrix SNP6.0 (Affymetrix, Santa Clara, CA, USA) arrays of the TOSE 1 and TOSE 4 cell lines, and a discrete copy number gain covering the CXCR4 gene locus 2q 136 588 303 --137 111 749 was found ( Figure 2a ). This amplicon contained two genes: CXCR4 and DARS. DARS has no known role in ovarian cancer, but CXCR4 is the only chemokine receptor commonly expressed on malignant ovarian epithelial cells in human cancer biopsies and cell lines 13, 22 and is implicated in ovarian cancer growth and spread. 14,15 CXCR4 copy number gain was confirmed by fluorescent in situ hybridisation ( Figure 2b : metaphase spread of TOSE 1), and images quantified ( Figure 2c ). The chromosome 2 centromere was also duplicated in TOSE cells. As karyotyping did not detect extra copies of chromosome 2, we suggest that two extra truncated chromosome 2 are present in TOSE cells, one of which contains the extra CXCR4. CXCR4 gene locus amplification was associated with increased CXCR4 mRNA levels in TOSE cells (Figure 2d ) (see inset for CXCR4 protein western blot); this was localised at the cell surface as detected by flow cytometry (Figure 2e ) and immunofluorescence (data not shown).
We tested the function of CXCR4 on TOSE cells using cell migration assays. IOSE cells did not migrate towards the sole ligand for CXCR4, CXCL12, but both TOSE lines gained this ability. Figure 3a shows a typical bell-shaped dose response curve for TOSE4 cells. This migration was CXCR4/CXCL12-specific as pre-incubation of the cells with two different CXCR4 antagonists, AMD3100 and CTCE9908, inhibited cell migration. TOSE cells did not migrate to another chemokine, CCL2 that binds to a different chemokine receptor, and neither IOSE nor TOSE cells expressed CXCR7, an alternative receptor for CXCL12 23 (data not shown). CXCR4 expression was stably silenced using shRNA (Figures 3b and c); this abrogated migration to CXCL12 (Figure 3d ). In soft agar, shCXCR4 TOSE cell colony diameter was 50% of colony size from parental cells or scrambled shRNA controls (Figure 3e ). There was also small but significant reduction in the number of colonies. Similar results were seen with shRNA in TOSE4 cells (data not shown). Hence, we conclude that CXCR4 enhances growth in soft agar. TOSE cells do not grow in immunocompromised mice IOSE25, TOSE 1 and 4 cells were injected i.p., into the ovary, or subcutaneously into immunodeficient mice, but no tumours were detected after 8 to 12 weeks observation. A positive control, the HGSOC cell line IGROV-1, grew to form extensive tumours within four to 6 weeks in littermates. We also explored the counterhypothesis that CXCR4 expression may keep the cells in a state of 'low grade transformation' by injecting shCXCR4 TOSE 1 cells or scrambled shRNA controls intraperitoneally or into the ovary of nude mice. IGROV-1 cells were again used as a positive control. Knockdown of CXCR4 did not render the TOSE 1 cells tumourigenic after 10 weeks of observation.
TOSE cells are hypermethylated at the CXCL12 promoter We previously reported that CXCR4-expressing malignant ovarian epithelial cells from advanced ovarian cancer also express the CXCR4 ligand CXCL12 in vitro and in vivo. 13, 22, 24, 25 However, TOSE cells expressed very low levels of CXCL12 mRNA and protein when compared with IOSE25 cells (Figure 5a ), or the ovarian cancer cell lines TOV21G and IGROV1. 15, 25 Epigenetic silencing of CXCL12 is found in colon and mammary carcinoma cells and is associated with metastasis to organs with high CXCL12 levels. 26, 27 We found that TOSE 1 and TOSE 4 cells were hypermethylated at the CXCL12 promoter (Figure 5b) . Treatment of cells with the demethylating agent 5-azacytidine plus the HDAC inhibitor trichostatin A restored CXCL12 mRNA to a level of expression similar to the IOSE25 cells (Figure 5c ).
Overexpression of CXCL12 in TOSE cells demonstrated no effect on the number of colonies formed in soft agar. However, the size of the colonies was doubled (Figure 5d ). CXCL12-expressing TOSE cells still failed to grow in SCID mice when implanted s.c. or i.p.
CXCR4, p53 and EGFR pathway expression in serous ovarian cancer biopsies TOSE cells demonstrate altered CXCR4 and p53 expression. To investigate whether CXCR4 and p53 are linked in patient biopsies, we tested whether a recently defined mutated TP53 gene expression signature 28 was associated with increased expression of CXCR4 pathway genes. This mutated TP53 gene expression signature was observed in 50 samples selected for highest levels of CXCR4 pathway gene expression (P ¼ 0.0089): high CXCR4 pathway expression is indicative of mutated TP53 expression profiles. Samples selected for high CXCR4 pathway expression was also associated with downregulation of p53 target genes (Po0.001) (Figure 6a ). In HGSOC, we conclude that mutated TP53 expression signature and decreased expression of p53 target genes are associated with high expression of CXCR4 pathway genes.
As TOSE shCXCR4 cells resulted in reduced EGFR expression (Figures 4a and b) , we also tested whether EGFR pathway genes were enriched in patient samples selected for high CXCR4 pathway expression. Genes differentially regulated between high CXCR4 and low CXCR4 pathways are enriched with genes from the EGFR pathway (Po0.001) (Figure 6b ).
DISCUSSION
Controversy remains over the cell of origin of HGSOC and the precise molecular events that occur during cellular transformation.
Our data indicate that cultures taken from the ovarian surface epithelium can transform into cells with mutations in TP53 and other genomic changes that are typical of advanced stages HGSOC. However, we cannot exclude the possibility that the NOSE25 cells collected from brushings from the ovarian surface epithelium may be fallopian in origin, given the close proximity of these two tissues and the common finding of endosalpingiosis in the female pelvis.
The TOSE cells were not fully malignant. However, they fulfilled the other markers of transformation: growth in soft agar, cytogenetic changes and alterations in morphology. TOSE cells also showed increased sensitivity to the oncolytic adenovirus dl922 --947 when compared with parental IOSE cells, suggesting that they have altered Rb pathways. 29 Following long-term culture, normal murine OSE and rat OSE cells transform spontaneously. 30 --32 However, human cells need to overcome greater barriers than murine cells to reach malignancy. 33 Soft agar may provide one selection pressure. In addition, the parental IOSE25 cells, although obtained from a donor without malignant ovarian disease, contained a missense heterozygous mutation in exon 5 of TP53, which may have contributed to cellular transformation, as this mutation is implicated in the development of chromosomal aberrations through inhibition of DNA ligation. 34 TOSE cells lost the mutant allele and gained a different TP53 missense mutation in exon 8 of the remaining allele, in a location that is commonly mutated in ovarian cancer. 6 Loss of the wild-type allele of TP53 has not been carefully reported in HGSOC 6,35 although our unpublished data estimate this in at least 80% of cases. In targeted human cell lines and in mouse models, loss of the wild-type allele confers significant advantage for the transformed cell. 35, 36 Loss of the wild-type allele may also be critical in human cancers as gain-of-function mutations in TP53 may be more important than putative dominant-negative effects. 37, 38 We can only speculate as to how a second mutation arose in the TOSE lines as synchronous mutations in TP53 are not reported, although different mutations have been observed between p53 signature lesions in the normal fallopian tube and HGSOC tissues. 39 As NOSE25 cells (from which the immortal cells were derived) had a very small population with R175H mutation, it is possible that, together with hTERT, these cells had a survival advantage in vitro. We cannot exclude the possibility that there was an even smaller population of cells with the R273H mutation that were not detected, even by digital PCR. It is important to note that HGSOC shows distinct cellular heterogeneity. 40 Preferential selection of TOSE mutant R273H clone may have occurred because R273 H has greater dominant-negative function and tumour-promoting properties than the R175H allele. 35 In addition, the resultant homozygous minor Arg72 allele has increased allelic expression of p53 when compared with Pro72 allele. 41 These observations are supported by data in this paper showing that TOSE cells have greater p53 immunoreactivity than IOSE25 cells. TOSE cells also demonstrated a change in expression of TP53 target genes compared with IOSE25, suggesting that the TP53 mutation in exon 8, TP53 LOH and nuclear immunoreactivity are associated with functional changes of p53 in TOSE cells.
TOSE cells contained a genomic amplification of the chemokine receptor CXCR4. This, to our knowledge, is the first report of chemokine receptor amplification. Chemokines and their receptors have important roles in cancer especially during metastasis. 42 Our results indicate that at least one chemokine receptor could be important in the early stages of cell transformation and suggest that CXCR4 and p53 pathways are linked in human ovarian cancers.
Gene amplicons are found in pre-neoplastic tissue, 43 and amplicons are indicative of candidate oncogenes. 44 Santarius et al. 45 proposed criteria for identifying oncogenes in areas that are amplified in cancer. In ovarian cancer, CXCR4 fulfils these criteria: CXCR4 expression correlates with clinical evidence; 14 CXCR4 expression leads to alterations in other genes in the same pathway; alterations in expression causes a biological effect and there is substantial evidence from animal studies. 15, 24, 25 However, as yet we have no evidence of CXCR4 amplification in HGSOC biopsies. Furthermore, amplification of CXCR4 may occur in precursor cells, but lost upon full malignancy.
Our data suggest that CXCR4 expression and TP53 mutation are intrinsically linked in ovarian cancer. In breast cancer, wild-type but not mutant TP53 represses CXCR4 expression and p53 rescue drugs (PRIMA-1 and CP-31398) reduced CXCR4 expression. 46 It was also recently suggested that TP53 mutation in cancer stem cells leads to CXCR4 upregulation. 47 TOSE cells have epigenetically silenced CXCL12. Cells with epigenetically silenced CXCL12 have increased metastatic potential in mammary carcinoma, 27 as they are able to follow chemokine gradients. There is increasing evidence for a new model of metastasis: pre-malignant cells migrate to distant sites of metastasis where they accumulate more mutations independently before growing tumours. 48 TOSE cells may represent premalignant HGSOC lesions that through epigenetically silenced CXCL12 are able to disseminate. They do not have sufficient genetic changes to form cancers, but further selection pressures may eventually lead to tumour growth.
CXCL12 expression is increased in late stage ovarian cancers and contributes to tumour growth. 22 In order for full malignancy to progress, any epigenetic silencing would need to be overcome. However, TOSE-CXCL12 cells did not grow when implanted into SCID mice, indicating that further abnormalities are necessary for full malignancy.
TOSE cells also display an enriched EGFR pathway, suggesting that these 'precursor' cells are primed to potentially interact with their ligands and have a survival advantage. It is proposed that cross-talk exists between CXCL12/CXCR4 and EGFR intracellular pathways that link signals of cell proliferation in ovarian cancer. 49 Understanding the significance of CXCR4 signalling in the earliest stages of HGSOC will require further study.
MATERIALS AND METHODS
Ovarian cell lines
Ovarian surface epithelial cells (IOSE25) immortalised and cultured as described. 12 IGROV-1 cells obtained from Dr Martin Ford (Glaxo R&D, Stevenage, UK) in 1998 and last underwent 16 loci STR authentication (LGC Standards, London, UK) in September 2011. They were cultured in RPMI 1640 supplemented with 10% FCS.
Cells were treated with 100 ng/ml CXCL12 (Peprotech, Rocky Hill, NJ, USA), 1 mg/ml AMD3100 (Sigma, St Louis, MA, USA) or 100 mg/ml CTCE-9908 (Chemokine Therapeutic Corp., Vancouver, Canada). Cell counts/circularity performed using Vi-Cell cell viability analyser (Beckman Coulter, High Wycombe, UK). TP53 sequencing and digital PCR Sequencing of exons 2 --11 and intron --exon boundaries of TP53 performed as described 50 with following modifications: PCR reactions performed in 25 ml; universal M13 forward and M13 reverse sequences included for bidirectional sequencing of each exon an alternative forward primer sequence of CAGGTCTCCCCAAGGCGCAC for sequencing exon 7
Microsatellite analysis
to avoid poor quality sequence from a poly A tract adjacent to previously described primer. Sequence data from TP53 aligned to reference NC_000017.9. Sequencing of KRAS, BRAF, CTNNB1 and PIK3CA and mutational analysis performed as described. 6 Digital PCR was performed using the Biomark microfluidic system (Fluidigm, South San Francisco, CA, USA) according to manufacturer's instructions. Samples were heated to 95 1C for 1 min and placed on ice. Reaction mixes contained 1 ml of 4 ng/ml cell line DNA, TaqMan Universal PCR mastermix (Applied Biosystems), 1 Â GE loading buffer (Fluidigm), 1800 nM forward and reverse primers and 400 nM of each germline and tumour-specific probe. Samples loaded onto a 12.765 Fluidigm digital chip containing 12 panels with each containing 765 chambers with a 6-nl reaction volume and thermocycled at 50 1C for 2 min; 95 1C for 10 min followed by 55 cycles of 95 1C for 15 s and 60 1C for 1 min.
Soft agar assay 5 Â 10 4 cells added to 0.35% agar in MCDB105/M199 supplemented medium above a base layer of 0.5% agar in 6-well plates. Following incubation, colonies stained with 0.005% crystal violet (Sigma) and scored.
Expression arrays and bioinformatics analysis RNA isolated using standard Trizol protocol, purified further with RNeasy kit (Qiagen, Hilden, Germany) according to manufacturer's recommendations. Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays used (Affymetrix). Probe synthesis and microarray hybridisation performed according to standard Affymetrix (Affymetrix) protocols at Barts Cancer Institute. Triplicate samples obtained per cell line. Microarray samples deposited at NCBI's Gene Expression Omnibus repository (GSE13763). Data analysed using Bioconductor 2.5 (http://bioconductor.org) running on R version 2.10.0. 51 Probe set expression measures calculated using Affymetrix Robust Multichip Average default method (Affymetrix). 52 Differential gene expression assessed between IOSE and TOSE sample groups using an empirical Bayes t-test (limma package). 53 P-values adjusted for multiple testing correction using Benjamini --Hochberg method. 54 2D hierarchical clustering of expression data using differentially expressed genes (adjusted P-value of 0.05 or more) between IOSE and TOSE samples performed. Samples clustered using 1---Pearson's correlation distance matrix and average linkage clustering. Genes clustered using Euclidean distance matrix and average linkage clustering using Cluster and visualised using Java TreeView. 55 p53 target genes and CXCR4 pathway genes extracted from Metacore pathway tool (GeneGo Inc, St Joseph, MI, USA). These are listed in Supplementary Tables S2 and S6. Copy number and LOH analysis Genomic DNA from cell lines extracted using DNA mini kit (Qiagen) and analysed using genome-wide Human SNP Array 6.0 (Affymetrix) according to manufacturer's instructions.
Data deposited at NCBI's repository (GSE25492). In-house Genome Orientated Laboratory File package used for data analysis. Hybridisation values normalised to median value on each array, and copy number determined based on log 2 ratio of signal intensity of TOSE DNA compared with IOSE25 DNA.
Fluorescent in situ hybridisation
Human BAC clone for CXCR4 (clone 809c23 from RPCI11.C) labelled with Spectrum Green dUTP (Abbot Molecular, Des Plaines, IL, USA) using nick translation enzyme (Abbot Molecular). Colcemid (2 ng/ml; Sigma) treatment overnight arrested cells in metaphase, and cells fixed with 3:1 methanol: acetic acid, dropped on slides, aged at 60 1C for 20 min, rinsed (2 Â SSC, 30 min, 37 1C) and dehydrated in an ethanol series. CXCR4 amplification was assessed using labelled BAC clone and a control probe for chromosome 2 centromere (CEP2) labelled with Spectrum Orange (Abbott Molecular). HyBrite denaturation/hybridisation system used (probes and slides co-denatured at 73 1C, 5 min). Hybridisation was carried out for 18 h at 37 1C, followed by washes in 0.4 Â SSC plus Tween (0.4%). Slides were counterstained with DAPI Prolong Gold (Molecular Probes, Invitrogen, Carlsbad, CA, USA) and images captured by Eclipse 80i microscope (Nikon, Tokyo, Japan) and Image-Pro Plus software (Media Cybernetics, Bethesda, MD, USA).
RNA extraction and real-time quantitative reverse transcription PCR analysis RNA was extracted from cell lines using Qiagen RNeasy (Qiagen). DNase treated RNA reverse transcribed with Moloney murine leukaemia virus reverse transcriptase (Promega, Southampton, UK) and real-time reverse transcription PCR analysis carried out using EGFR, CXCR4 or CXCL12 (FAM) and 18 s rRNA (VIC) specific primers and probes with ABI PRISM 7700 Sequence Detection System instrument and software (PE Applied Biosystem, Warrington, UK). Expression values were normalised (DC t ) to 18 s rRNA. Fold difference ¼ 2
ÀðDCtÞ .
Western blotting
Cell lysates run on 10% NuPAGE gels (Invitrogen), transferred to PVDF membrane (Millipore, Watford, UK). Antibodies against CXCR4 (Abcam, Cambridge, UK), EGFR (Cell Signaling, Boston, MA, USA) and b-actin (Sigma) followed by a horseradish peroxidase-conjugated secondary antibody (GE Healthcare, Chalfont St Giles, UK) incubation allowed visualisation using enhanced chemiluminescence (GE Healthcare).
Immunofluoresence staining
Cells plated on Lab-Tek chamber slides (Nalge Nunc International, ThermoFisher Scientific, Rochester, NY, USA), fixed with paraformaldehyde (4%) and permeabilised in 0.5% Triton X-100, washed in 0.1% Triton X-100 and stained overnight with p53 (BD Biosystems, Franklin Lakes, NJ, USA) or isotype control (R&D systems, Minneapolois, MN, USA) antibodies (1:200). Primary antibodies were washed with PBS and Alexa Fluor 488 secondary antibody (Invitrogen) applied. Slides were counterstained with DAPI Prolong Gold (Invitrogen) and images captured by Nikon Eclipse 80i microscope and Image-Pro Plus software (Media Cybernetics).
Cell motility assay
Cell migration was assayed using Falcon Transwells (24-well format, 8 mm pore; BD Biosciences). 5 Â 10 5 IOSE or TOSE cells (pretreated with AMD3100 (1 mg/ml), CTCE9908 (100 mg/ml) or control for 15 min) were added to upper chamber, and medium alone or medium supplemented with CXCL12 was added to lower chamber. Following incubation for 18 h at 37 1C in 5% CO 2 , migrated cells to lower chamber were stained using DiffQuick (Dade Behring, Dü dingen, Switzerland) and counted.
CXCR4 shRNA transfection TOSE cells were transfected with pSilencer containing a hairpin sequence against CXCR4 (Ambion, Austin, TX, USA) using siPORT XP-1 (Ambion). Selection with hygromycin (100 mg/ml) was carried out after 24 h for 30 days.
CXCL12 ELISA CXCL12 concentrations in cell supernatants (72 h culture) measured using Quantikine ELISA kits following manufacturer's instructions (R&D Systems). Sensitivity of assay: 18 pg/ml. Bisulfite treatment and methylation specific PCR Genomic DNA (2 mg) was bisulfite treated using EpiTect Bisulfite kit (Qiagen). Methylation-specific PCR was carried out as previously described. 26 Demethylation TOSE cells treated with 5-aza-2 0 -deoxycytidine (2 mM) for 5 days, and/or trichostatin A (100 ng/ml) for 24 h before RNA extraction, cDNA generation and RT --PCR analysis as described previously.
Statistical analysis
Statistical analysis carried out using Prism 5 software (GraphPad, La Jolla, CA, USA). Statistical significance was calculated using Student's t-test.
